REGENXBIO appoints George Migausky board chairman

Daniel Tassé will remain on REGENXBIO’s board after stepping down as Lead Independent Director.

Rhea-AI Filing Summary

REGENXBIO Inc. announced changes to its board leadership. Kenneth T. Mills resigned from the board on October 14, 2026, effective October 21, 2026. The company said Mills recently became chief executive officer of another company and intends to focus his efforts on that role; his departure was not related to any disagreement with REGENXBIO on operations, policies or practices. In connection with Mills’s departure, the board appointed George Migausky as Chairman. Daniel Tassé stepped down as Lead Independent Director because the new Chairman is an independent director, and will remain a board member.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

Lead Independent Director, Corporate Governance Guidelines, independent director

3 terms

Lead Independent Director technical

"stepped down from his position as Lead Independent Director"

A lead independent director is a board member who is not part of company management and is chosen to coordinate and represent the other independent directors, often running sessions without the CEO, helping set meeting agendas, and serving as a liaison between shareholders and the board. For investors, this role signals stronger, more balanced oversight—like a neutral referee who helps ensure decisions are fair, transparent and focused on protecting shareholder interests.

Corporate Governance Guidelines technical

"In accordance with the Company’s Corporate Governance Guidelines"

A company’s corporate governance guidelines are a set of written rules and practices that explain how its board and executives make decisions, oversee risks, and hold themselves accountable—think of them as the organization’s playbook for fair and responsible leadership. Investors care because these guidelines shape how transparent decision-making is, reduce the chance of surprises or conflicts, and influence long‑term stability and trust, much like house rules keep a household running smoothly.

independent director technical

"as the new Chairman is an independent director"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is RGNX’s new board chairman?

George Migausky was appointed Chairman of REGENXBIO’s board in connection with Kenneth T. Mills’s departure. The company said the new Chairman is an independent director.

Why did Kenneth T. Mills resign from RGNX’s board?

Kenneth T. Mills resigned after recently becoming chief executive officer of another company and intending to focus his efforts on that role. REGENXBIO said his decision was not related to any disagreement with the company on its operations, policies or practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/16/2026 - 07:00 AM EDT Accepted by SEC EDGAR 10/16/2026 - 07:00 AM EDT Learn about SEC filing dates

false000159087700015908772026-10-142026-10-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 14, 2026

REGENXBIO Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37553	47-1851754
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
9804 Medical Center Drive
Rockville, Maryland				20850
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (240) 552-8181

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		RGNX		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the “Board”) of REGENXBIO Inc. (the “Company”) effective October 21, 2026. Mr. Mills recently became chief executive officer of another company and intends to focus his efforts on his new role. Mr. Mills’ decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.

In connection with Mr. Mills’ departure, the Board appointed George Migausky as Chairman of the Board (“Chairman”). In accordance with the Company’s Corporate Governance Guidelines, Daniel Tassé has stepped down from his position as Lead Independent Director, as the new Chairman is an independent director, but will remain a member of the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			REGENXBIO Inc.
Date:	October 16, 2026	By:	/s/ Patrick J. Christmas II
			Patrick J. Christmas II Executive Vice President, Chief Strategy & Legal Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.4 KB